Retatrutide Cleared Two More Phase 3 Trials — and Missed the Thing That Mattered Most
Lilly’s retatrutide passed TRIUMPH-2 and TRIUMPH-3 in July 2026 — but missed on cardiovascular events, and the FDA filing slipped to Q1 2027. An honest read.
-
-
The FDA Did Not Approve Six Peptides: What the July 2026 Compounding Vote Actually Was
An FDA panel recommended six of seven peptides for the 503A compounding list on 23-24 July 2026. That is not approval. What the vote did and did not do.
-
Which Peptides Has Andrew Huberman Said He Uses?
Which peptides Andrew Huberman has said he personally uses — pinealon, BPC-157, sermorelin — and what the primary literature actually shows about each.
-
Every Peptide Bryan Johnson Has Tried — and Why He Dropped Most of Them
Bryan Johnson has trialed CJC-1295, HGH, tirzepatide, cerebrolysin, epithalon, follistatin and BPC-157. A sourced look at what he measured, kept, and dropped.
-
Joe Rogan’s Peptide Use, Fact-Checked
Joe Rogan says he uses BPC-157 and TB-500 to heal injuries. We fact-check the claims against the actual literature — what holds up, what doesn’t.
-
Peter Attia on Peptides and Longevity Drugs, Fact-Checked
A source-checked look at where Peter Attia actually stands on NMN, rapamycin, metformin, GLP-1 drugs and BPC-157 — and where popular hype runs past the evidence.
-
Gary Brecka’s Peptide and Longevity Claims, Fact-Checked
A source-checked look at Gary Brecka’s claims on methylene blue, BPC-157, NAD+ and hydrogen — what the literature actually shows, and where certainty outruns data.
-
Three Semaglutides: How One Molecule Split Into Three Legal Categories
The GLP-1 shortage spawned a compounding boom. As the FDA winds it down, semaglutide is left as three distinct things that share a molecule’s regulatory story but not a legal status — and a research vial is the most misunderstood of them.
-
Bryan Johnson’s Peptide Stack, Fact-Checked: What the Evidence Actually Says
Blueprint’s founder has run dozens of peptides through his body and his biomarkers. Ranked by evidence, his protocol separates the plausible from the speculative — and his most instructive move was quitting something that “felt” like it worked.
-
Is Research-Market Retatrutide Legit? The Drug, the Vial, and the Gap Between Them
Retatrutide is a real phase III triple agonist that produced some of the largest weight-loss figures in trial history. The vial sold on a research-chemical site is not that drug — and here is the honest distinction.
